Lonza Signs Agreement with Index Ventures for Biological Products - - BioPharm International

ADVERTISEMENT

Lonza Signs Agreement with Index Ventures for Biological Products



Lonza, a custom biologics manufacturing organization and Index Ventures, a venture capital investment firm, have signed an agreement for process development and cGMP production for all biological products in the portfolio of companies where Index is the major investor. Over the course of the agreement, additional development and manufacturing projects will be added to the product list, as future investments are made by Index.

Source: Lonza

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

USP Awards Analytical Research
August 15, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
Guilty Plea to Importing Illegal Cancer Drugs
August 15, 2014
Amgen Recalls Aranesp Prefilled Syringes
August 15, 2014
Report Predicts Generics Production Return to US
August 15, 2014
Author Guidelines

Click here